Every Form 4 that Whitehawk Therapeutics, Inc. (WHWK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow WHWK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WHWK filings page.
Whitehawk Therapeutics, Inc. (WHWK) reported that its chief financial officer, Scott M. Giacobello, received two equity awards on September 15, 2026. He was granted a stock option for 118,476 shares of common stock at an exercise price of $4.09 per share, expiring on September 15, 2036; 25% of the option vests on the one-year anniversary of the September 15, 2026 Vesting Commencement Date, and 1/48 of the total vests monthly thereafter until fully vested after four years. He also received 118,476 restricted stock units, each representing one share of common stock, which will vest 100% on the one-year anniversary of the same Vesting Commencement Date, correcting an earlier Form 4 that had an incorrect vesting schedule. No Rule 10b5-1 trading plan is reported.
Whitehawk Therapeutics, Inc. (WHWK) reported that Chief Technical Operations Officer Bryan Ball received two equity awards on September 15, 2026: a stock option covering 91,633 shares of common stock with an exercise price of $4.09 per share, and an award of 91,633 restricted stock units, each representing one share of common stock.
The stock option vests over four years, with 25% of the shares vesting on the one-year anniversary of the Vesting Commencement Date of September 15, 2026, and the remainder vesting in equal monthly installments so that all shares are vested by the four-year anniversary. The restricted stock unit award vests 100% on the one-year anniversary of the same Vesting Commencement Date, assuming Mr. Ball continues as a service provider. The amended filing corrects an earlier Form 4 that had reported an incorrect vesting schedule for the restricted stock units. No transactions were made under a Rule 10b5-1 trading plan.
Whitehawk Therapeutics, Inc. (WHWK) reported that Chief Scientific Officer David Dornan received equity awards on September 15, 2026. He was granted a stock option for 85,887 shares of common stock at an exercise price of $4.09 per share, expiring on September 15, 2036, vesting 25% after one year from the Vesting Commencement Date and monthly thereafter over four years, subject to continued service. He also received 85,887 restricted stock units, each representing one share of common stock, which will vest 100% on the one-year anniversary of the Vesting Commencement Date, subject to continued service. The amendment corrects the previously reported vesting schedule for the RSU award. No Rule 10b5-1 trading plan is reported.
Whitehawk Therapeutics, Inc. (WHWK) reported that its chief executive officer, David James Lennon, received a stock option grant for 193,957 shares of common stock at an exercise price of $4.09 per share and a separate grant of 193,957 restricted stock units on September 15, 2026. The option vests 25% on the one-year anniversary of the September 15, 2026 vesting commencement date, with the remainder vesting in equal monthly installments over the following three years, and expires on September 15, 2036. The RSU award is structured so that 100% of the shares vest on the one-year anniversary of the same vesting commencement date, and this amendment corrects an earlier report that had shown an incorrect vesting schedule.
Whitehawk Therapeutics, Inc. (WHWK) reported that Chief Medical Officer Margaret Dugan received two equity awards on September 15, 2026: a stock option and a restricted stock unit (RSU) grant, each covering 81,250 shares of Common Stock, with no Rule 10b5-1 trading plan indicated.
The stock option has an exercise price of $4.09 per share and expires on September 15, 2036; subject to Dr. Dugan continuing as a Service Provider, 25% of the option vests on the one-year anniversary of the September 15, 2026 Vesting Commencement Date and the remaining 75% vests in equal monthly installments over the following three years. The RSU award represents a contingent right to receive one share of Common Stock per unit and, as corrected in this amended filing, is scheduled to vest 100% on the one-year anniversary of the same September 15, 2026 Vesting Commencement Date, contingent on continued service.
Whitehawk Therapeutics, Inc. (WHWK) reported equity awards to Chief Executive Officer David James Lennon on September 15, 2026. He received a stock option for 193,957 shares of Common Stock at an exercise price of $4.09 per share, expiring September 15, 2036, and 193,957 Restricted Stock Units, each RSU representing one share of Common Stock.
Both awards vest based on continued service: for the option, 25% vests on the one-year anniversary of the September 15, 2026 Vesting Commencement Date and 1/48 of the total vests monthly thereafter until fully vested after four years; for the RSUs, 25% vests on each of the first four anniversaries of that Vesting Commencement Date.
Whitehawk Therapeutics, Inc. (WHWK) reported that its Chief Financial Officer, Scott M. Giacobello, received two equity awards on September 15, 2026. He was granted stock options covering 118,476 shares of common stock at an exercise price of $4.09 per share, and a separate award of 118,476 Restricted Stock Units, each RSU representing one share of common stock. Both awards vest over time starting from a Vesting Commencement Date of September 15, 2026, subject to his continued service, with the options vesting monthly over four years and the RSUs vesting in four equal annual installments.
Whitehawk Therapeutics, Inc. (symbol: WHWK) is the issuer of record for a Form 4 filing submitted to the SEC. Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
Whitehawk Therapeutics, Inc. (WHWK) reported that its Chief Medical Officer, Margaret Dugan, received equity-based compensation on September 15, 2026. She was granted options to purchase shares of common stock and a separate award of restricted stock units, each covering 81,250 shares, with multi-year vesting tied to continued service.
Whitehawk Therapeutics, Inc. (symbol: WHWK) is the issuer of record for a Form 4 filing submitted to the SEC. Dornan David reported acquisition or exercise transactions in this Form 4 filing.
Whitehawk Therapeutics, Inc. (WHWK) reported that Chief Scientific Officer David Dornan received new equity awards. On September 15, 2026 he was granted options to purchase 85,887 shares of common stock at $4.09 per share, expiring September 15, 2036, plus 85,887 restricted stock units. Both awards vest over four years starting from a Vesting Commencement Date of September 15, 2026, contingent on continued service, and no Rule 10b5-1 trading plan is reported.
Whitehawk Therapeutics, Inc. (WHWK) reported equity compensation grants to its Chief Technical Operations Officer, Bryan Ball. On September 15, 2026, he received a stock option for 91,633 shares of common stock at an exercise price of $4.09 per share, expiring on September 15, 2036. The option vests 25% on the one-year anniversary of the Vesting Commencement Date of September 15, 2026, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. On the same date, he also received 91,633 restricted stock units, each representing one share of common stock, vesting 25% on the first anniversary of the Vesting Commencement Date and 25% on each of the next three anniversaries, also conditioned on continued service. No Rule 10b5-1 trading plan is reported for these awards.
Whitehawk Therapeutics, Inc. (WHWK) reported that director Vijay K. Iyengar received a stock option grant on September 9, 2026. The award covers 76,080 shares of common stock at an exercise price of $4.19 per share, expiring on September 9, 2036, and is held directly.
According to the award terms, the option vests in 36 equal monthly installments, with one thirty-sixth of the shares vesting each month so that all shares are fully vested on the three-year anniversary of the September 9, 2026 grant date. No Rule 10b5-1 trading plan is reported for this grant.
Whitehawk Therapeutics, Inc. director Anupam Dalal reported two equity-related acquisitions. He was granted 38,040 stock options with an exercise price of $4.16 per share, expiring in 2036; all options vest on the earlier of one year from the June 12, 2026 grant date or immediately before the next annual stockholders’ meeting, subject to continued service.
Dalal also reported an indirect acquisition of 1,275,510 shares of common stock at $3.92 per share, held through Acuta Capital Fund, LP and Acuta Opportunity Fund, LP, bringing his reported indirect holdings via these funds to 4,685,912 shares. He has voting and investment authority over these fund holdings but disclaims beneficial ownership except to the extent of his pecuniary interest. Separately, he holds 1,130 common shares directly.
Whitehawk Therapeutics director Baiteng Zhao received a grant of stock options as compensation. On the grant date, Zhao was awarded options for 38,040 shares of common stock at an exercise price of $4.16 per share, expiring on June 12, 2036. All options vest 100% after about one year or just before the next annual stockholder meeting, as long as Zhao continues serving the company.
Whitehawk Therapeutics director Emma Reeve received a stock option grant, giving her the right to buy 38,040 shares of common stock at an exercise price of $4.16 per share. The option was granted as a compensation award with no cash paid at grant.
The option expires on June 12, 2036. All 38,040 shares subject to the option vest 100% on the earlier of one year after the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting, as long as she continues as a service provider. Following this grant, she holds options covering 38,040 shares directly.
Whitehawk Therapeutics director Richard E. Maroun received a grant of stock options covering 38,040 shares of common stock. The options have an exercise price of $4.16 per share and expire on June 12, 2036. All 38,040 option shares will vest in a single tranche, subject to his continued service, on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting following that date. After this award, he holds 38,040 derivative securities directly.
Whitehawk Therapeutics director Mohammad Hirmand received a new stock option grant covering 38,040 shares of common stock. The option has an exercise price of $4.16 per share and expires on June 12, 2036.
All 38,040 option shares will vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the next annual stockholder meeting, as long as he continues as a service provider. Following this grant, he holds 38,040 stock options directly from this award.
Whitehawk Therapeutics director Neil Desai received a new stock option grant. The Form 4 shows an award of options covering 38,040 shares of common stock at an exercise price of $4.1600 per share, expiring on June 12, 2036.
All 38,040 option shares vest in a single tranche, subject to Mr. Desai continuing as a service provider. Vesting occurs on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting after that grant date.
Whitehawk Therapeutics director Caley Castelein received a new stock option grant covering 38,040 shares of common stock. The option has an exercise price of $4.16 per share and expires on June 12, 2036. Following this grant, Castelein holds stock options for 38,040 underlying shares directly.
According to the award terms, all 38,040 option shares vest 100% if Castelein continues as a service provider until the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately prior to the next annual stockholder meeting after that grant date.
Whitehawk Therapeutics, Inc. reported that director and 10% owner Behzad Aghazadeh was granted stock options covering 38,040 shares of common stock. The options have an exercise price of $4.16 per share and expire on June 12, 2036.
According to the terms, all 38,040 underlying shares vest in a single tranche if the reporting person continues to be a service provider through the earlier of the one-year anniversary of the grant date or the day immediately before the next annual shareholder meeting, with a grant date of June 12, 2026. The filing is made jointly by Avoro Capital Advisors LLC, Avoro Ventures LLC, and Dr. Aghazadeh, who each disclaim beneficial ownership beyond their pecuniary interest.
Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
Whitehawk Therapeutics, Inc. reported that its Chief Medical Officer, Margaret Dugan, received a grant of 19,132 shares of common stock on May 14, 2026. The shares were valued at $3.92 per share for reporting purposes, bringing her direct holdings to 19,132 shares. This is a compensation-related award, not an open-market purchase.
Whitehawk Therapeutics executive Bryan Ball reported a stock-based compensation grant on Common Stock. On May 14, 2026, he acquired 51,020 shares at an indicated value of $3.92 per share as a grant or award, rather than an open-market purchase. Following this award, his direct holdings in Whitehawk Therapeutics increased to 448,126 Common Stock shares, reflecting a routine compensation-related equity grant instead of a discretionary market trade.
Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported a compensation-related stock award on a Form 4. He acquired 38,265 shares of common stock on May 14, 2026 in a transaction classified as a grant or award at a reference price of $3.92 per share. Following this award, his directly held ownership increased to 333,489 shares of Whitehawk Therapeutics common stock. This filing reflects an equity grant rather than an open-market purchase or sale.
Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported an equity compensation grant of Common Stock. He acquired 51,021 shares at an indicated value of $3.92 per share as a grant, bringing his direct holdings to 569,643 shares after the transaction.
Whitehawk Therapeutics director Caley Castelein reported new share and warrant awards. He received a grant of 255,102 shares of Common Stock at $3.92 per share, bringing his directly held Common Stock to 274,796 shares.
Entities associated with him, specifically KVP Capital, LP, now hold 2,165,998 shares of Common Stock indirectly and a Pre-Funded Warrant to acquire 2,072,756 additional Common shares at an exercise price of $0.0001 per share. The warrant can be exercised on or after May 14, 2026, but includes a 4.99% beneficial ownership cap. Castelein is Managing Director of KVP Capital and disclaims beneficial ownership in those indirect holdings except for his pecuniary interest.
Whitehawk Therapeutics, Inc. reported that accounts managed by Avoro Capital Advisors LLC acquired 6,377,714 pre-funded warrants to buy common stock in a private placement. The warrants have a token exercise price of $0.0001 per share and were priced at $3.9199 per warrant.
The warrants become exercisable on or after May 12, 2026, but a 19.99% ownership blocker limits exercises so the reporting persons do not exceed 19.99% of Whitehawk’s outstanding common stock. Following this transaction, the reporting persons report beneficial ownership of 14,710,714 pre-funded warrants, while expressly disclaiming beneficial ownership beyond their pecuniary interest.
Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported broker-assisted dispositions of common stock primarily to cover tax obligations from vesting equity awards. On April 15 and 16, he sold 77,000 shares at $3.86 and 141,600 shares at $4.13 per share, respectively. A footnote explains these represent sales to satisfy tax withholding obligations tied to restricted stock unit vesting, rather than discretionary open-market selling. After these transactions, he continues to hold 295,224 shares of common stock directly.
Whitehawk Therapeutics officer Bryan Ball reported broker-assisted sales of company common stock to cover taxes on vested restricted stock units. On April 13, he sold 26,389 shares at $3.46 per share, and on April 14 he sold 92,460 shares at $3.64 per share. A footnote clarifies these transactions were solely to satisfy tax withholding obligations related to RSU vesting, making them compensation-driven rather than discretionary portfolio sales. After these transactions, Ball directly held 397,106 shares of Whitehawk Therapeutics common stock.
Whitehawk Therapeutics insider Bryan Ball reported dispositions of company common stock that were executed solely to cover taxes on equity compensation. On April 9 and 10, he completed broker-assisted sales totaling 56,596 shares at prices between $3.43 and $3.57 per share.
The footnote explains these trades were conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units, rather than discretionary open-market sales. After these transactions, Ball still directly holds 515,955 shares of Whitehawk Therapeutics common stock.
Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported selling 14,500 shares of common stock on April 9, 2026 at $3.38 per share. According to the filing, this broker-assisted sale was made solely to satisfy tax withholding obligations tied to vesting restricted stock units. After the transaction, he directly holds 518,622 shares of Whitehawk common stock.
Whitehawk Therapeutics director and CEO David James Lennon sold shares to cover taxes tied to equity vesting. Over April 6–8, 2026, he executed broker-assisted sales totaling 260,427 shares of Common Stock at prices around $3.40–$3.51 per share.
According to a footnote, these transactions were made solely to satisfy his tax withholding obligations in connection with the vesting of restricted stock units, rather than discretionary open-market sales. After these dispositions, he directly holds 533,122 Common Stock shares.
Whitehawk Therapeutics, Inc. granted Chief Scientific Officer David Dornan a stock option to acquire 282,340 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036.
According to the vesting terms, if he continues as a service provider, 25% of the option will vest on the one-year anniversary of the Vesting Commencement Date of April 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years.
Whitehawk Therapeutics, Inc. reported that its Chief Medical Officer, Margaret Dugan, received a grant of stock options covering 283,157 shares of common stock. The options have an exercise price of $3.54 per share and expire on April 1, 2036.
These options were granted as compensation and will vest over four years. Twenty five percent of the shares will vest on the one-year anniversary of the April 1, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments until fully vested.
Whitehawk Therapeutics, Inc. executive Bryan Ball reported compensation-related equity activity. He exercised 366,532 restricted stock units, receiving the same number of common shares at a price of $0.00 per share. Following this RSU conversion, he directly held 572,551 shares of common stock.
Ball was also granted a new stock option for 250,058 shares of common stock with an exercise price of $3.54 per share, expiring on April 1, 2036. According to the footnotes, RSUs vest 100% one year after the April 1, 2025 vesting commencement date, and the option vests over four years starting April 1, 2026, assuming continued service.
Whitehawk Therapeutics, Inc. reported that Chief Financial Officer Scott M. Giacobello exercised restricted stock units and received a new stock option grant. He exercised 473,902 restricted stock units, receiving the same number of common shares, and now directly holds 502,002 common shares. He was also granted a stock option for 300,677 shares of common stock at an exercise price of $3.54 per share, expiring on April 1, 2036. According to the footnotes, the RSU award vests 100% on the one-year anniversary of the April 1, 2025 vesting commencement date, while the option vests over four years starting from an April 1, 2026 vesting commencement date.
Whitehawk Therapeutics, Inc. director and CEO David James Lennon exercised restricted stock units and received a new stock option award, while selling a small block of shares to cover taxes. He exercised 775,828 restricted stock units, receiving the same number of Common Stock shares. He also received a stock option for 831,148 shares of Common Stock at an exercise price of $3.54 per share, expiring on April 1, 2036, subject to multi‑year vesting. To satisfy tax withholding obligations related to RSU vesting, a broker-assisted sale of 26,858 shares of Common Stock was executed at $3.48 per share. After these transactions, Lennon directly holds 793,549 Common Stock shares.
Whitehawk Therapeutics CEO David James Lennon reported routine equity compensation activity. He exercised restricted stock units into 16,250 shares of Common Stock at a conversion price of $0.0000 per share on March 1, 2026. On March 2, 2026, 5,100 Common Stock shares were sold at $3.3096 per share in a broker-assisted sale to satisfy tax withholding obligations related to the RSU vesting, rather than a discretionary market sale. After these transactions, he directly holds 44,579 shares of Common Stock and 32,500 restricted stock units.
Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported compensation-related stock activity. On March 1, 2026, he exercised restricted stock units, converting 6,750 RSUs into the same number of common shares at a stated price of $0.0000 per share. A related entry shows 13,500 RSUs remaining after this vesting. On March 2, 2026, he completed a broker-assisted sale of 2,594 common shares at an average price of $3.3096 per share to satisfy tax withholding obligations tied to the RSU vesting. Following these transactions, he directly held 28,100 common shares.
Whitehawk Therapeutics officer Bryan Ball reported routine equity compensation activity. On March 1, 2026, he exercised restricted stock units, acquiring 5,000 shares of Common Stock at a conversion price of $0.00 per share, increasing his direct holdings.
On March 2, 2026, Ball disposed of 1,834 shares of Common Stock at an average price of $3.3096 per share in a broker-assisted transaction used to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he directly held 206,019 shares of Common Stock and 10,000 Restricted Stock Units.
Whitehawk Therapeutics, Inc. reported new equity compensation grants to its Chief Medical Officer. On December 1, 2025, the officer received a stock option covering 650,000 shares of common stock at an exercise price of $2.26 per share, along with 55,309 restricted stock units (RSUs).
The option vests over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date of December 1, 2025, and the remaining shares vesting in equal monthly installments so that the option is fully vested four years after that date, subject to continued service. All 55,309 RSUs are scheduled to vest in full on the one-year anniversary of the same vesting commencement date, also conditioned on the officer continuing as a service provider.